

POWERING AFFORDABLE CARE

while meeting quality metrics



We understand that, as a health center provider, **you face unique challenges**. Not only do you care for a significant percentage of high-cost, high-need patients, but you're also tasked with helping to ensure your center stays financially healthy. We can help, with testing that supports your quality reporting needs to bolster funding and improve patient outcomes.

Testing to help you meet and report quality metrics

As your health center prepares for upcoming reporting deadlines, our testing options can help you close gaps in care and improve quality scores.

	UDS CQM	HEDIS® Measure	HRSA CHQR	PCMH Core CQM	GPRA Measure	Test Name/Code(s)
Diabetes Care	Diabetes Control (CMS122v8) (HbA1c >9%) Healthy People 2030 Objective D-03 (11.6%)	Comprehensive Diabetes Care (CDC) (adults ages 18–75 with diabetes type 1 or type 2, HbA1c control <8%)	Uncontrolled Diabetes (HbA1c >9%) ≥16.20%	Comprehensive Diabetes Care (HbA1c testing)	Diabetes Control (% of patients with diabetes with poor glycemic control - HbA1c > 9%, Target rate = 16.8%)	Cardio IQ® Hemoglobin A1c, 91732 Metabolic Risk Panel, 39447 Cardio IQ® Diabetes Risk Panel with Score, 92026
Chronic Kidney Disease Screening	Healthy People 2030 Objective CKD-01 (12.8%)	Kidney Health Evaluation for Adults with Diabetes (adults ages 18–85 with diabetes [type 1 and type 2])	N/A	N/A	N/A	Kidney Profile, 39165
Colorectal Cancer Screening	CRC Screening (CMS130v8) Healthy People 2030 Objective C-07 (74.4%)	CRC Screening (COL) (adults ages 50–75)	CRC Screening (≥42.02%)	CRC Screening (adults ages 50–75)	CRC Screening (Adults ages 50–75, Target rate = 32.6%)	Fecal Globin by Immunochemistry (InSure®), 11290
Cervical Cancer Screening	Cervical Cancer Screening (CMS124v8) Healthy People 2030 Objective C-09 (84.3%)	Cervical Cancer Screening (CCS) (women ages 21–64) Chlamydia Screening (CHL) (females ages 16–24 and identified as sexually active [by claims or pharmacy data])	Cervical Cancer Screening (≥55.67%)	Cervical Cancer Screening (women ages 21–64)	Cervical Cancer Screening (Women ages 24–64, Target rate = 38.4%)	Image-Guided Pap with Age-Based Screening Protocols, 91384 Image-Guided Pap with Age-Based Screening with CT/NG, 91385 Image-Guided Pap with Age-Based Screening with CT/NG, Trichomonas, 91386
Sexually Transmitted Infection Screening	Healthy People 2030 Objective STI-01 (76.5%) HIV Screening (CMS349v3) Chlamydia Screening for Women (CMS153v10)	Chlamydia Screening (CHL) (females ages 16–24 and identified as sexually active [by claims or pharmacy data])	Chlamydia Screening Gonorrhea Screening	N/A	N/A	Chlamydia/Neisseria gonorrhoeae RNA, TMA, Urogenital, 11363 Trichomonas vaginalis RNA, Qualitative, TMA, Pap Vial, 19550

We work with you to manage key challenges more effectively, allowing you to focus on delivering the highest-quality care.

Panel components may be ordered separately: Metabolic Risk Panel: Cholesterol, Total (91717, C117); Triglycerides (91718, C119); HDL Cholesterol (91719, C118) Lipid Panel (91716, C906), Hemoglobin A1c (91732, C145), Apolipoprotein B (91726, C123), Insulin, Intact, LC/MS/MS (93103), Insulin Resistance Panel with Score (36509, 1388); Cardio IQ® Diabetes Risk Panel with Score: Cardio IQ® Glucose (91947), Cardio IQ® Hemoglobin A1c (91732), Cardio IQ® Cholesterol, Total (91717), Cardio IQ® HDL Cholesterol (91719), Cardio IQ® Triglycerides (91718); Kidney Profile: eGFR (375), Albumin, Random Urine with Creatinine (6517)

UDS CQM = Uniform Data System Clinical Quality Measures; HEDIS = Healthcare Effectiveness Data and Information Set; HRSA = Health Resources and Services Administration; Community Health Quality Recognition (CHQR); PCMH = Patient-Centered Medical Home



Now's the time to step up preventive care efforts

As SARS-CoV-2 (COVID-19) has compounded health disparities for your patient population, it's more important than ever to **achieve key quality measures**. Our testing can support a range of metrics, from diabetes care to cervical cancer screening.



Assessing risk and managing diabetes and chronic kidney disease

Our individual tests and innovative panels range from early identification of insulin resistance and metabolic risk to the diagnosis of prediabetes and diabetes, as well as monitoring for progression to chronic kidney disease.



Improving cancer screening rates

We offer a range of solutions and services that can make cancer testing more accessible to you and your patients, including InSure® ONE™, a convenient, at-home, colorectal screening test.



Insights for all stages of a woman's life

Our cervical cancer screening cotesting solutions have been shown to identify more cases of pre-cancer and cancer than either Pap or HPV testing alone, while our age-based Smart Codes make it easy to order both the cervical cancer screening and STI tests your patients need.

Drive better patient outcomes while optimizing reimbursements.

Contact your Quest Diagnostics sales representative to learn more about the testing that supports your quality reporting efforts.

[QuestDiagnostics.com](https://www.questdiagnostics.com)

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2022 Quest Diagnostics Incorporated. All rights reserved. SB10942 3/2022

